Vascular Peroxide 1 Promotes Ox-Ldl-induced Programmed Necrosis in Endothelial Cells Through a Mechanism Involving Β-Catenin Signaling

Yin-Zhuang Zhang,Lei Wang,Jie-Jie Zhang,Xiao-Ming Xiong,Di Zhang,Xuan-Meng Tang,Xiu-Ju Luo,Qi-Lin Ma,Jun Peng
DOI: https://doi.org/10.1016/j.atherosclerosis.2018.04.031
IF: 5.3
2018-01-01
Atherosclerosis
Abstract:Background and aims: Vascular peroxidase 1 (VPO1) plays a key role in mediation of cardiovascular oxidative injury. This study aims to determine whether VPO1 can promote programmed necrosis of endothelial cells and the underlying mechanisms. Methods and results: Human umbilical vein endothelial cells (HUVECs) were incubated with oxidized low-density lipoprotein (ox-LDL, 100 mu g/mL) for 48 h to induce cell injury, which showed an elevation in cell necrosis (reflected by the increased propidium iodide (PI) positive-staining cells, LDH release and decreased cell viability), concomitant with an increase in programmed necrosis-relevant proteins including receptor-interacting protein kinase 1/3 (RIPK1/3), p-RIPK3 and mixed lineage kinase domain like (MLKL); these phenomena were attenuated by necrostatin-1(Nec-1) and RIPK3 siRNA. Meanwhile, VP01 was up-regulated in ox-LDL-treated endothelial cells accompanied by a decrease in GSK-3 beta activity and p-beta-catenin levels, and an elevation of beta-catenin levels; these phenomena were reversed in the presence of VP01 siRNA or hypochlorous acid (HOCI) inhibitor; replacement of ox-LDL with HOCI could also induce endothelial programmed necrosis and activate the beta-catenin signaling; beta-catenin inhibitor could also suppress ox-LDL-induced RIPK-dependent necrosis. In hyperlipidemic patients, the plasma level of VP01 was obviously increased concomitant with an elevation in plasma levels of RIPK1, RIPK3 and MLKL, and they were positively correlated. Conclusions: VP01 plays an important role in promotion of endothelial programmed necrosis under hyperlipidemic conditions through activation of beta-catenin signaling. It may serve as a novel therapeutic target for prevention of endothelial dysfunction in hyperlipidemia. (C) 2018 Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?